Intellipharmaceutics International Inc
TSX:IPCI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Intellipharmaceutics International Inc
Other Current Liabilities
Intellipharmaceutics International Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intellipharmaceutics International Inc
TSX:IPCI
|
Other Current Liabilities
$1.1m
|
CAGR 3-Years
382%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other Current Liabilities
$38m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-21%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other Current Liabilities
CA$21.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Other Current Liabilities
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other Current Liabilities
$38.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other Current Liabilities
CA$24.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
|
Intellipharmaceutics International Inc
Glance View
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.
See Also
What is Intellipharmaceutics International Inc's Other Current Liabilities?
Other Current Liabilities
1.1m
USD
Based on the financial report for Aug 31, 2023, Intellipharmaceutics International Inc's Other Current Liabilities amounts to 1.1m USD.
What is Intellipharmaceutics International Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
30%
Over the last year, the Other Current Liabilities growth was 6 041%. The average annual Other Current Liabilities growth rates for Intellipharmaceutics International Inc have been 382% over the past three years , 30% over the past five years .
